Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fennec awarded U.S. patent for PEDMARK product » 06:11
09/21/20
09/21
06:11
09/21/20
06:11
FENC

Fennec

$6.54 /

+0.36 (+5.83%)

Fennec announced that the…

Fennec announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled "Anhydrous Sodium Thiosulfate and Formulations Thereof." As suggested by the title, the patent captures the unique anhydrous form of the active ingredient in Fennec's PEDMARK product, as well as related methods of synthesis. This patent is eligible for listing in the U.S FDA Orange Book, and reflects Fennec's strategy to expand and diversify its intellectual property portfolio to obtain protection for the PEDMARK product. PEDMARK was granted Orphan Drug Designation by the FDA in 2004. This designation, along with a patent portfolio that includes a previously issued method of use patent from March 2020 and this recent to-be-issued composition patent, further strengthens the position of PEDMARK as the first potential treatment for the prevention of platinum induced ototoxicity in pediatric patients.

ShowHide Related Items >><<
FENC Fennec
$6.54 /

+0.36 (+5.83%)

FENC Fennec
$6.54 /

+0.36 (+5.83%)

08/12/20 Wedbush
Fennec price target lowered to $11 from $18 at Wedbush
06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
FENC Fennec
$6.54 /

+0.36 (+5.83%)

  • 30
    Apr
FENC Fennec
$6.54 /

+0.36 (+5.83%)

Over a month ago
Recommendations
Fennec price target lowered to $11 from $18 at Wedbush » 07:27
08/12/20
08/12
07:27
08/12/20
07:27
FENC

Fennec

$6.66 /

-3.48 (-34.32%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on Fennec to $11 from $18 and keeps an Outperform rating on the shares. The analyst notes the company received a Complete Response Letter from the FDA regarding its NDA for PEDMARK saying the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that need to be resolved prior to approval. In response to the CRL, the company plans to request and hold a Type A meeting with the agency within the next couple months, Nierengarten adds. Importantly, the analyst points out that the issues that resulted in the CRL related purely to the drug's manufacturing facility, and so no new clinical or preclinical data will need to be generated. Given uncertainty around when the company will next engage with the FDA, what specific conditions will need to be satisfied at the manufacturing facility, and how long it will take to satisfy them, he is now incorporating a preliminary approval delay of about 10 months, or to mid-2021.

ShowHide Related Items >><<
FENC Fennec
$6.66 /

-3.48 (-34.32%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$6.66 /

-3.48 (-34.32%)

  • 30
    Apr
FENC Fennec
$6.66 /

-3.48 (-34.32%)

Conference/Events
Wedbush to hold a virtual conference » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
ABUS

Arbutus Biopharma

$3.44 /

-0.21 (-5.75%)

, BHVN

Biohaven Pharmaceutical

$59.86 /

-2.09 (-3.37%)

, IDRA

Idera Pharmaceuticals

$2.17 /

-0.04 (-1.81%)

, ALNA

Allena Pharmaceuticals

$1.40 /

-0.08 (-5.41%)

, CLSD

Clearside Biomedical

$1.72 /

-0.07 (-3.91%)

, VIE

Viela Bio

$36.02 /

-1.94 (-5.11%)

, AQST

Aquestive Therapeutics

$6.60 /

-0.35 (-5.04%)

, LQDA

Liquidia Technologies

$5.40 /

-0.48 (-8.16%)

, UTHR

United Therapeutics

$109.46 /

-1.49 (-1.34%)

, NTLA

Intellia Therapeutics

$19.53 /

-0.89 (-4.36%)

, KURA

Kura Oncology

$20.66 /

-0.67 (-3.14%)

, NBRV

Nabriva Therapeutics

$0.72 /

-0.0096 (-1.32%)

, MYOK

MyoKardia

$101.01 /

-3.86 (-3.68%)

, MRUS

Merus

$12.99 /

-0.23 (-1.74%)

, RCUS

Arcus Biosciences

$22.99 /

+0.03 (+0.13%)

, RARE

Ultragenyx

$82.73 /

-2.34 (-2.75%)

, MRSN

Mersana Therapeutics

$18.52 /

-1.52 (-7.58%)

, KALA

Kala Pharmaceuticals

$8.94 /

-0.3 (-3.25%)

, FENC

Fennec

$6.66 /

-3.48 (-34.32%)

, FPRX

Five Prime

$4.76 /

-0.4 (-7.75%)

, STRO

Sutro Biopharma

$8.49 /

+0.03 (+0.35%)

, SURF

Surface Oncology

$5.92 /

-0.04 (-0.67%)

, SWTX

SpringsWorks Therapeutics

$44.36 /

-1.1 (-2.42%)

, ISEE

Iveric bio

$4.39 /

-0.145 (-3.20%)

Wedbush Pacgrow…

Wedbush Pacgrow Healthcare Virtual Conference will be held on August 11-12.

ShowHide Related Items >><<
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRUS Merus
$12.99 /

-0.23 (-1.74%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

08/10/20 Piper Sandler
Piper says Biohaven post-earnings pullback a 'great buying opportunity'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
12/06/19 Wedbush
Allena Pharmaceuticals selloff 'overdone,' says Wedbush
CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

07/30/20 Oppenheimer
United Therapeutics price target raised to $165 from $155 at Oppenheimer
06/25/20 Credit Suisse
United Therapeutics price target raised to $145 from $129 at Credit Suisse
06/25/20 H.C. Wainwright
United Therapeutics price target raised to $125 from $85 at H.C. Wainwright
04/07/20
United Therapeutics participates in a conference with JPMorgan
NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MRUS Merus
$12.99 /

-0.23 (-1.74%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
07/01/20 JPMorgan
Ultragenyx price target raised to $84 from $76 at JPMorgan
07/01/20 Wedbush
Ultragenyx price target raised to $91 from $83 at Wedbush
MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

06/24/20 BTIG
Mersana Therapeutics price target raised to $32 from $21 at BTIG
05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
06/01/20 Oppenheimer
Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
05/27/20 JPMorgan
Kala Pharmaceuticals assumed with an Overweight at JPMorgan
FENC Fennec
$6.66 /

-3.48 (-34.32%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRUS Merus
$12.99 /

-0.23 (-1.74%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

  • 30
    Jun
  • 18
    Jun
  • 03
    Jun
  • 29
    May
  • 29
    May
  • 28
    May
  • 12
    May
  • 13
    May
  • 06
    May
  • 30
    Apr
  • 11
    Mar
  • 29
    Jan
  • 24
    Dec
  • 13
    Dec
  • 06
    Dec
  • 05
    Nov
  • 03
    Oct
  • 13
    Sep
RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

Conference/Events
Wedbush to hold a virtual conference » 08:35
08/11/20
08/11
08:35
08/11/20
08:35
ABUS

Arbutus Biopharma

$3.65 /

-0.13 (-3.44%)

, BHVN

Biohaven Pharmaceutical

$61.95 /

-5.72 (-8.45%)

, IDRA

Idera Pharmaceuticals

$2.21 /

+0.12 (+5.74%)

, ALNA

Allena Pharmaceuticals

$1.48 /

-0.015 (-1.00%)

, CLSD

Clearside Biomedical

$1.79 /

+0.035 (+1.99%)

, VIE

Viela Bio

$37.96 /

+0.79 (+2.13%)

, AQST

Aquestive Therapeutics

$6.95 /

+0.66 (+10.49%)

, LQDA

Liquidia Technologies

$5.88 /

-0.35 (-5.62%)

, UTHR

United Therapeutics

$110.95 /

-1.84 (-1.63%)

, NTLA

Intellia Therapeutics

$20.42 /

+0.63 (+3.18%)

, KURA

Kura Oncology

$21.33 /

+0.95 (+4.66%)

, NBRV

Nabriva Therapeutics

$0.73 /

-0.005 (-0.68%)

, MYOK

MyoKardia

$104.87 /

+1.36 (+1.31%)

, MRUS

Merus

$13.22 /

+0.02 (+0.15%)

, RCUS

Arcus Biosciences

$22.96 /

+1.18 (+5.42%)

, RARE

Ultragenyx

$85.07 /

+0.37 (+0.44%)

, MRSN

Mersana Therapeutics

$20.04 /

-0.23 (-1.13%)

, KALA

Kala Pharmaceuticals

$9.24 /

+0.35 (+3.94%)

, FENC

Fennec

$10.14 /

+1.14 (+12.67%)

, FPRX

Five Prime

$5.16 /

-0.46 (-8.19%)

, STRO

Sutro Biopharma

$8.46 /

-0.05 (-0.59%)

, SURF

Surface Oncology

$5.96 /

-0.01 (-0.17%)

, SWTX

SpringsWorks Therapeutics

$45.46 /

+0.31 (+0.69%)

, ISEE

Iveric bio

$4.53 /

+0.11 (+2.49%)

Wedbush Pacgrow…

Wedbush Pacgrow Healthcare Virtual Conference will be held on August 11-12.

ShowHide Related Items >><<
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRUS Merus
$13.22 /

+0.02 (+0.15%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

07/27/20 B. Riley Securities
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

08/10/20 Piper Sandler
Piper says Biohaven post-earnings pullback a 'great buying opportunity'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
12/06/19 Wedbush
Allena Pharmaceuticals selloff 'overdone,' says Wedbush
CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

07/30/20 Oppenheimer
United Therapeutics price target raised to $165 from $155 at Oppenheimer
06/25/20 Credit Suisse
United Therapeutics price target raised to $145 from $129 at Credit Suisse
06/25/20 H.C. Wainwright
United Therapeutics price target raised to $125 from $85 at H.C. Wainwright
04/07/20
United Therapeutics participates in a conference with JPMorgan
NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MRUS Merus
$13.22 /

+0.02 (+0.15%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
07/01/20 JPMorgan
Ultragenyx price target raised to $84 from $76 at JPMorgan
07/01/20 Wedbush
Ultragenyx price target raised to $91 from $83 at Wedbush
MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

06/24/20 BTIG
Mersana Therapeutics price target raised to $32 from $21 at BTIG
05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
06/01/20 Oppenheimer
Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
05/27/20 JPMorgan
Kala Pharmaceuticals assumed with an Overweight at JPMorgan
FENC Fennec
$10.14 /

+1.14 (+12.67%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRUS Merus
$13.22 /

+0.02 (+0.15%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

  • 30
    Jun
  • 18
    Jun
  • 03
    Jun
  • 29
    May
  • 29
    May
  • 28
    May
  • 12
    May
  • 13
    May
  • 06
    May
  • 30
    Apr
  • 11
    Mar
  • 29
    Jan
  • 24
    Dec
  • 13
    Dec
  • 06
    Dec
  • 05
    Nov
  • 03
    Oct
  • 13
    Sep
RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

Hot Stocks
Fennec sinks 34% after receiving FDA Complete Response Letter on NDA for PEDMARK » 06:21
08/11/20
08/11
06:21
08/11/20
06:21
FENC

Fennec

$10.14 /

+1.14 (+12.67%)

In pre-market trading,…

In pre-market trading, shares dropped 34% to $6.74.

ShowHide Related Items >><<
FENC Fennec
$10.14 /

+1.14 (+12.67%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$10.14 /

+1.14 (+12.67%)

  • 30
    Apr
FENC Fennec
$10.14 /

+1.14 (+12.67%)

Hot Stocks
Fennec receives FDA Complete Response Letter on NDA for PEDMARK » 06:05
08/11/20
08/11
06:05
08/11/20
06:05
FENC

Fennec

$10.14 /

+1.14 (+12.67%)

Fennec Pharmaceuticals…

Fennec Pharmaceuticals announced that it received a Complete Response Letter on August 10 from the U.S. FDA regarding its New Drug Application for PEDMARK for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients greater than or equal to1 month to 18 years of age with localized, non-metastatic, solid tumors. According to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK. The company plans to request a Type A meeting to discuss the issues and other matters that were described in the CRL pertaining to the steps required for the resubmission of the NDA for PEDMARK. Importantly, no clinical safety or efficacy issues were identified during the review and there is no requirement for further clinical data. "We are steadfast in our commitment to reducing the risk of life-long hearing loss for children receiving cisplatin chemotherapy who currently have no approved therapies for this devastating condition," said Rosty Raykov, CEO of Fennec. "We will work closely with our manufacturer and the FDA to fully address the issues raised in the letter as expeditiously as possible."

ShowHide Related Items >><<
FENC Fennec
$10.14 /

+1.14 (+12.67%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$10.14 /

+1.14 (+12.67%)

  • 30
    Apr
FENC Fennec
$10.14 /

+1.14 (+12.67%)

Conference/Events
FDA PDUFA Date for Fennec Pharmaceuticals Pedmark is August 10, 2020  08:38
08/10/20
08/10
08:38
08/10/20
08:38
FENC

Fennec

$9.00 /

+0.33 (+3.81%)

 
ShowHide Related Items >><<
FENC Fennec
$9.00 /

+0.33 (+3.81%)

FENC Fennec
$9.00 /

+0.33 (+3.81%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$9.00 /

+0.33 (+3.81%)

  • 30
    Apr
FENC Fennec
$9.00 /

+0.33 (+3.81%)

Earnings
Fennec reports Q2 EPS (21c), consensus (18c) » 06:16
08/05/20
08/05
06:16
08/05/20
06:16
FENC

Fennec

$9.00 /

+0.24 (+2.74%)

"We continue to work…

"We continue to work with the FDA as a part of their review process in advance of the pending PEDMARK PDUFA date of August 10," said Rosty Raykov, CEO of Fennec Pharmaceuticals. "Our organization and commercial team have been actively preparing for launch readiness, and, as we await the FDA's decision, we believe that we are well positioned to commercialize PEDMARK, if approved, during the third quarter of 2020." Cash and cash equivalents were $38.7M as of June 30, with no funded debt.

ShowHide Related Items >><<
FENC Fennec
$9.00 /

+0.24 (+2.74%)

FENC Fennec
$9.00 /

+0.24 (+2.74%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$9.00 /

+0.24 (+2.74%)

  • 30
    Apr
FENC Fennec
$9.00 /

+0.24 (+2.74%)

Over a quarter ago
Conference/Events
Fennec to host special shareholder meeting virtually » 11:25
06/22/20
06/22
11:25
06/22/20
11:25
FENC

Fennec

$9.08 /

+0.03 (+0.33%)

Special Shareholder…

Special Shareholder Meeting to vote on the election of six directors and to appoint auditors and fix auditors' remuneration will be held virtually on June 22 at 12 pm. Webcast Link

ShowHide Related Items >><<
FENC Fennec
$9.08 /

+0.03 (+0.33%)

FENC Fennec
$9.08 /

+0.03 (+0.33%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$9.08 /

+0.03 (+0.33%)

FENC Fennec
$9.08 /

+0.03 (+0.33%)

Conference/Events
Fennec to host special shareholder meeting virtually » 08:31
06/22/20
06/22
08:31
06/22/20
08:31
FENC

Fennec

$9.05 /

-0.3 (-3.21%)

Special Shareholder…

Special Shareholder Meeting to vote on the election of six directors and to appoint auditors and fix auditors' remuneration will be held virtually on June 22 at 12 pm. Webcast Link

ShowHide Related Items >><<
FENC Fennec
$9.05 /

-0.3 (-3.21%)

FENC Fennec
$9.05 /

-0.3 (-3.21%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FENC Fennec
$9.05 /

-0.3 (-3.21%)

FENC Fennec
$9.05 /

-0.3 (-3.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.